Henry, who works at Crowshall Veterinary Services in Norfolk, graduated from the Royal Veterinary College in 2018.
He is the lead products export vet for Crowshall and was instrumental in the business’s preparation for Brexit.
He is also one of the founding ‘green champions’ at the practice, which has become the first specialist poultry practice to be accredited with Investors in the Environment.
The panel of seven judges from said that within just three years Henry has gained much experience, showing evidence that he has contributed to reduced antibiotic usage as well as improved biosecurity and improved bird welfare, health and production for his clients.
They said: “He has clearly shown he has worked with colleagues as a team, and has introduced new initiatives in his practice including improving mental health of staff and assisting in sustainability.”
James Porritt, National Pig and Poultry Sales Manager of award sponsors Zoetis, said all three finalists were very strong candidates: “It was great to see the work they have all done recognised at the awards.
"It was fantastic to see Henry win and hope the award spurs him on to continue his bright future in the poultry industry.”
Photo: Henry Lamb holding the Young Farm Vet trophy, alongside Jonathan Agnew (left) and James Porritt of the award sponsors Zoetis
Eprinex Multi contains eprinomectin and is effective against the adult stages of the major gutworm species affecting sheep and goats, and the lungworm Dictyocaulus filaria.
Merial highlights two studies which show how treatment can overcome the productivity impact of a parasite burden. In the first, dairy ewes showed a significant increase in milk yield following treatment with Eprinex Multi compared to untreated animals.1
The second study, which looked at interactions between nutrition and gastrointestinal parasites in French dairy goats concluded that subclinical parasite infections induced a persistent decrease in milk yield, ranging from 2.5 to 10%.2
Sioned Timothy, Technical Manager, UK & ROI, Merial Animal Health said: "Merial recognises the need for sustainable, effective disease prevention strategies both to optimise the health and welfare of livestock, and to protect their productivity.
"The small dairy ruminant sector in the UK is small but growing: the registration of Eprinex Multi allows us to communicate and work with this industry to promote best practice in parasite control.
"Eprinex Multi brings a new active ingredient to the sheep and goat wormer market and provides vets and farmers with an additional tool to use alongside good management practices, as part of an integrated parasite control strategy.
"It has the advantage of zero milk withhold, which allows dairy animals to be treated at the optimal time without the concern of lost milk.
"Merial values this very important sector of the livestock industry and is excited to offer this new development to the marketplace. Eprinex Pour On has proven itself in the cattle sector over the last two decades, and the registration of Eprinex Multi with indications for use in goats and sheep alongside cattle offers new opportunities for managing animal health, welfare and production.
References
Hysolv says the vaccine, which was developed by IDT Biologika, has been used successfully in Germany, where 1.7 million doses have been prescribed. The company says field trials have shown that vaccination not only protected against clinical signs of influenza but also resulted in improvements in reproduction and piglet performance.
Two 1 ml doses of the inactivated vaccine can be injected intramuscularly three weeks apart to pigs from 56 days old, providing immunisation to the majority of animals within seven days.
Hysolv director, Geoff Hooper said: "Swine flu can be devastating to a herd and this vaccine will broaden protection, particularly when used with our existing vaccine Respiporc FLU3, which we are strongly advising."
Respiporc FLU3 protects against three other strains of swine flu (H1N1, H1N2 and H3N2). Hysolv says that when used together, the two vaccines protect pigs against the most relevant strains in the British Isles.
Geoff added: "There have been several flu pandemics throughout the years – the latest in 2009. It is not possible to predict the emergence of a pandemic strain accurately but this vaccine combined with Respiporc FLU3 will greatly decrease the chance of pigs becoming infected."
They say this approach could lead to a reduction in the number of vaccines that need to be administered to each bird.
Vaccines that target multiple diseases are in high demand due to the many viruses that can circulate simultaneously in flocks. Protecting against the most dangerous diseases with one vaccine could reduce overall vaccination costs for poultry producers and decrease the number of times that birds need to be handled.
The researchers demonstrated that a gene editing system called CRISPR/cas9 can be used to insert a gene of the IBD virus into the currently used Marek’s disease vaccine virus. The added genetic material protects poultry against IBD in addition to the protection already offered by the Marek’s disease vaccine, meaning that bird owners would only need to use one vaccine instead of two.
Other vaccines generated by conventional methods can achieve a similar result, but by using the CRISPR/cas9 system the Pirbright researchers say they have been able to insert the IBD gene far more quickly, easily and accurately than the methods that have been used before. This will significantly reduce the time needed to generate new vaccines.
Professor Venugopal Nair, joint leader of the research at Pirbright said: "The method we have created with CRISPR/cas9 really increases the scope of how we edit the Marek’s disease vaccine to include other virus components. Now we have shown that the gene-edited vaccine protects against both Marek’s disease and IBD, we are looking at inserting more genes from other viruses."
The team intend to generate a vaccine that will be able to protect against multiple avian diseases and will next target two high consequence poultry viruses - avian influenza virus and the Newcastle disease virus. The flexibility of the new method also means that as the viruses evolve, the vaccine virus can be easily edited to include new genes which protect against emerging strains.
The Pirbright Institute says there has been huge commercial interest in using this technology to develop novel vaccines, so it intends to partner vaccine manufacturing companies to bring CRISPR/cas9 edited vaccines to market.
This scientific paper can be found in the Vaccine journal and was funded by the Biotechnology and Biological Sciences Research Council (BBSRC); grant numbers BB/P016472/1 BB/L014262/1.
Photo: Cells infected with the Marek's disease vaccine virus, HVT, (green) expressing the inserted infectious bursal disease virus gene, VP2 (red). Cell nuclei are shown in blue. © Dr Na Tang, The Pirbright Institute 2018.
BVA has announced that it is launching a pilot of VETS.TV, and invites you to come and preview the service at its stand at BSAVA. Anyone willing to surrender their name and email address will also be entered into a prize draw to win an HP 530 Celeron M 440 laptop computer.
VETS.TV is an internet television site run jointly by the BVA and Ten Alps Publishing which will be available via a microsite of http://www.bva.co.uk/. The pilot includes custom-made videos on MRSA, litigation and stress management, a series of interviews with key veterinary figures and a number of specially acquired programmes.
The change has come about following a review of the assurance scheme's standards, when it was decided that all Red Tractor vets should be members of PVS, not just those carrying out Real Welfare assessments, as was previously the case.
Other changes in the review focus on the responsible use of antibiotics and a number of the animal medicine standards have been strengthened.
Red Tractor says the PVS membership requirement is in line with another new standard which will require veterinary surgeons to declare they only prescribe antibiotics for use on Red Tractor pig units in accordance with the PVS Prescribing Principles for Antimicrobials.
Red Tractor technical manager Joanna King said: "Ensuring every Red Tractor registered vet is a PVS member will help keep them abreast of the most recent version of the Prescribing Principles, along with other guidelines and publications."
Assessors undertaking Red Tractor farm assessments can verify whether the retained farm vet is a current PVS member through their membership number which is required on the quarterly veterinary report forms.
Membership numbers can be checked against an online PVS membership checker.
The National Office of Animal Health (NOAH) has launched a new 'Use Medicines Responsibly' campaign.
The main thrust of the campaign is an initiative by NOAH to encourage pharmaceutical companies to add: 'Use Medicines Responsibly' as a strapline to their own advertising campaigns, with a link to the NOAH information resource for prescribers and users of animal medicines: www.noah.co.uk/responsible.
Speaking at the NOAH annual members' conference in Northampton, NOAH chief executive Phil Sketchley said: "NOAH believes responsible promotion of animal medicines to be an important link in the chain towards responsible use. Companies' promotional material can educate prescribers and users of animal medicines to the benefit of their animals' health and welfare.
"We believe this new advice resource, with the reminder on advertisements, will help."
Animalcare has launched Emdocam (meloxicam 20mg/ml), a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class for use in cattle, pigs and horses.
According to the company, Emdocam disrupts the inflammatory cascade by inhibiting prostaglandin synthesis. It is a potent and preferential inhibitor of COX-2, permitting sufficient COX-1 sparing activity. It has analgesic and anti-inflammatory effects. When administered in a single dose to cattle, it has long acting anti-endotoxic, anti-pyretic and anti-inflammatory effects for up to three days.1,2
In cattle, it is indicated for bovine respiratory disease (BRD), clinical mastitis and calf scour. Animalcare says early use of meloxicam for BRD reduces pyrexia and pain, especially in young calves and improves feed intake. Meloxicam plus an antibiotic significantly reduced the extent of lung lesions, leading to improved clinical efficacy and daily liveweight gain in comparison with animals treated with antibiotics alone, for example oxytetracycline,3 florfenicol4and tilmicosin. 5
In the case of clinical mastitis, Animalcare says that used adjunctively with an antibiotic, Emdocam helps relieve local and systemic inflammation, returns the udder to a normal condition and reduces the polymorphonuclear leucocytes (PMN) response. In a large scale, double-blinded study in New Zealand, the addition of meloxicam to antibiotic therapy resulted in lower Somatic Cell Counts and a reduced risk of culling in dairy cows with mild clinical mastitis.6
Calf scour treated with meloxicam, as a supportive therapy, can improve calf well-being and reduce morbidity. In a double-blinded, controlled study, the use of meloxicam improved daily water and feed intake, added greater average bodyweight (bw) gain and helped calves to wean earlier. 7
In horses, administered IV at 3.0ml/100kg bw, Emdocam can be used for musculo-skeletal disorders, as well as colic, resulting in reduced pain and inflammation. In a study of 18 horses comparing flunixin with meloxicam and designed to determine the effect on recovery of ischemic-injured jejunum, meloxicam was found to be a useful alternative for the post-operative treatment of colic. 8
Emdocam is also indicated in pigs for non-infectious locomotive disorders and as an adjunctive therapy with an antibiotic in puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Tony Liepman from Animalcare said: "Emdocam is competitively priced whether used on its own or adjunctively with a long-acting intramuscular (IM) antibiotic, such as Florgane suspension for the treatment of BRD in calves. This, coupled with its long lasting, low volume (2.5ml/100kg bw in cattle), single dose administration, by intravenous (IV) or subcutaneous (SC) injection, makes Emdocam a highly efficacious and practical NSAID."
Emdocam is a POM-V medicine and available as 50 and 100ml multi-dose vials. Withdrawal period in cattle for meat and offal is 15 days and in pigs for meat and offal is 5 days. In horses for meat and offal it is 5 days. In Florgane [POM-V], the withdrawal period for meat and offal is 37 days in cattle and not to be used in cattle producing milk for human consumption
Cattle
Amongst the speakers were Catherine Oxtoby MRCVS, Risk Manager at the Veterinary Defence Society, and Dr Huw Stacey, director of clinical services at Vets4Pets.
Dr Stacey explained how Vets4Pets and Companion Care practices are embracing a culture of sharing information when things don’t go according to plan in practice.
He said: "We all face challenges in the workplace, and this event focused on how different professions can share ideas and good practice and how they find solutions to any challenges.
"The culture of aviation and maritime is one of minimising risk and putting safety first, and it is fascinating to compare their approach to that found in medicine and veterinary.
"One common theme we discussed was the wellbeing of both professionals and patients or clients, with tiredness being at the top of the list of things that can negatively affect wellbeing and performance.
"Both aviation and maritime recognised that long shifts, particularly overnight, needed to be reduced in order to improve the outcome for everyone.
"In veterinary and human medicine, tiredness and long shifts are often worn as a badge of honour and being tired at work was something that should be admired, rather than addressed.
"But, tired vets are effectively neglecting themselves and their own wellbeing, which in turn leads to pets not receiving the best level of care in practice.
"This is something we’re taking seriously at Vets4Pets and Companion Care, and we’re currently looking at ways to decrease the risk of overworked and tired vets and vet nurses."
Another area of discussion was around the reporting of near misses and when things don’t go right, and how veterinary professionals need to identify and share the learnings from these events, not only within their practice, but with the wider profession too.
He said: "We need to continually emphasise the concept of a ‘just’ culture, to ensure our colleagues feel confident about reporting incidents open and honestly."
"It is not in the interests of the professional, the patient or the client to bottle things up, and at Vets4Pets and Companion Care we’re encouraging all of our practices to adopt the VDS VetSafe system, which provides a mechanism for sharing incident reports across the profession, enabling us all to learn from them to the benefit of our patients."
On top of that, over 25% of vets said they don't talk to their farmer clients about the disposal of empty pharmaceutical waste.
The survey also found that while veterinary surgeons are aware that both glass and shatterproof plastic vials are incinerated, over 65% of those questioned believed that glass vials were more environmentally friendly, when in fact, the company says its CLAS (Ceva Layered Anti Shatter) shatterproof plastic vials have 33% less impact on the environment from cradle to grave2.
Ceva is producing a range of support materials, including tailored social media and newsletter content, to help vets to raise awareness of their pharmaceutical waste disposal service and drive improvements across the industry.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "As an industry we should be doing all that we can to improve our environmentally friendly credentials.
“Ceva will continue to invest in innovative eco-friendly technology for livestock injectables and pioneer improvements to help ensure best practice throughout the industry.”
For further information, or to request a pharmaceutical waste disposal service support pack, contact your local Ceva account manager or call 01494 781510.
Norbrook Laboratories Ltd has launched a second generation Eprinomectin Pour On solution with zero milk withhold and a 10 day meat withdrawal period. Eprizero, for beef and dairy cattle, is indicated for the treatment and prevention of a range of economically damaging gutworm and lungworm infections and external parasites in a pour on application. It offers zero milk withhold and an improved meat withdrawal period of 10 days. Andrew Hillan MVB MRCVS, Director of Veterinary Science, Norbrook Laboratories Ltd., said: "Norbrook has launched Eprizero to offer vets and farmers a more versatile alternative in the treatment of economically damaging worms and external parasites. The active ingredient in Eprizero, Eprinomectin, is both potent and fast-acting and is supported by independent studies which show increased milk yield, improved fertility and increased dry matter intake following treatment. With a zero milk and 10 day meat withdrawal and waterproof properties, Eprizero offers real versatility to vets and farmers in terms of when and where they treat. It is this versatility that we believe will make Eprizero the gold standard in anthelmintic treatment for prolonged infestations of gut worm and lung worm in both dairy and beef cattle." Eprizero is available in four sizes - 250ml, 1L, 2.5L and 5L - with a free 75ml gun supplied with the two larger pack sizes. It is administered using a 75ml dispensing gun to enable accurate application. Eprizero is registered for use in the UK and Ireland and is available to order from your local Norbrook Sales Representative.
The kit contains the ergonomically designed Henke-Sass Wolf injector with an adjustable dose selector, five single piece Intranasal RSP nozzles – with ‘luer’ lock attachment, which supports easier removal, cleaning and/or replacement – and instructions for use.
For more information, contact your local MSD Animal Health account manager.
Dechra says necrotic enteritis can be treated with a variety of therapeutic antibiotics but that the first choice antibiotics¹ for treatment are narrow spectrum antibiotics, like phenoxymethylpenicillin.
Phenocillin is an 800 mg/g powder for use in drinking water. It is lactose free, and Dechra says its high solubility makes it ideal for concentrated stock solutions and convenient for modern poultry farming. There is a zero withdrawal time so egg production is unaffected.
Dechra Brand Manager Emma Jennings said: “Necrotic enteritis is the most common bacterial disease in modern broiler flocks that can be financially devastating for farmers.
"The high concentration means easy dosage and handling with less waste and the lactose free formula reduces the risk of biofilm development resulting in a high quality and effective product, supporting the responsible use of antimicrobials.
"Phenocillin is a highly effective treatment and we anticipate it will become the preferred solution for veterinary professionals and end users to treat this disease that can very suddenly devastate broiler flocks."
For more information, visit: http://bit.ly/2nAboGU
Norbrook has announced the re-launch of its range of intramammary tubes for lactating and dry cows, to promote holistic herd health and responsible use of antimicrobials.
The company’s range, which includes products across a number of antibiotic classes, primarily targets clinical cases of mastitis in lactating cows, and removal or prevention of infection around the dry period.
Chris Geddes MRCVS, Marketing Manager at Norbrook, says the re-launch is focused on modernising the range and making it clearer for practice staff and farmers to avoid confusion between lactating cow and dry cow products: “We have a wide range of 11 products containing a variety of antimicrobials: for example Duofast is the only lactating cow product to contain trimethoprim and sulfadiazine. We are working with vets to promote responsible use by farmers, for example through the use of our teat sealant Noroseal for Selective Dry Cow Therapy."
The full range includes Duofast, Lactaclox, Cefimam LC, Combiclav, Noroclav and Multiject for the lactating cow; Cefimam DC, Noroclox, Bovaclox and Bovaclox DC Xtra for the dry cow; and teat sealant Noroseal.
Norbrook has also produced a best practice guide to mastitis control, available for vets in English and Polish, which can be shared with farmers.
Chris added: "We recognise the need to reduce overall use of antimicrobials, especially for disease prevention – as well as using non-antimicrobial products such as teat sealants. These practices, together with the recent focus on using older classes of antimicrobials, mean that as an industry we need to adopt a holistic and targeted approach to herd health management.
"We believe that by providing additional information to aid with prevention of disease, and re-launching our intramammary range to make it clearer when products should be used, we can help to achieve that."
Norbrook says the full range of products is in stock, but some wholesalers may hold components of the old range as the new range is phased in.
Forum Animal Health is launching a new programme designed for transition cows to help avoid milk fever relapses: the Milk Fever Pack.
According to the company, the new Milk Fever Pack provides a continuous and complete supply of readily available oral calcium to avoid relapses which also gives the cow extra support until her system is back in control. Unlike intravenous calcium, oral calcium will not suppress parathyroid hormone (PTH) release and therefore will not turn off the cow's natural mechanism to regulate blood calcium levels.
Each pack contains one sachet of Agger's® Fresh Cow which supplies essential calcium, energy and rehydrates the cow; and two tubes of Botonic® Calcium which create a mild metabolic acidosis to enable the cow to mobilise calcium efficiently.
Forum Animal Health says the new Milk Fever Pack has been developed in close collaboration with a leading veterinary nutritionist to allow veterinary surgeons to be involved at an earlier stage. The veterinary surgeon can then leave a follow-up protocol for the client to use, helping to avoid milk fever relapses. It gives veterinary surgeons a chance to introduce standard operating procedures into herd health plans bringing better control of milk fever on farms.
For more information, please contact Forum Animal Health on 01737 781416 or animal.health@forumgroup.co.uk.
The new guidelines strongly recommend an overall reduction in the use of all classes of medically important antibiotics in food-producing animals, including complete restriction of these antibiotics for growth promotion and disease prevention without diagnosis. Healthy animals should only receive antibiotics to prevent disease if it has been diagnosed in other animals in the same flock, herd, or fish population.
WHO says that where possible, sick animals should be tested to determine the most effective and prudent antibiotic to treat their specific infection. Antibiotics used in animals should be selected from those WHO has listed as being "least important" to human health, and not from those classified as "highest priority critically important", as they are often the last line, or one of a limited number of treatments available to treat serious bacterial infections in humans.
The new guidelines were informed by a systematic review published in The Lancet Planetary Health which found that interventions that restrict antibiotic use in food-producing animals reduced antibiotic-resistant bacteria in these animals by up to 39%1.
Dr Kazuaki Miyagishima, Director of the Department of Food Safety and Zoonoses at WHO said: "Scientific evidence demonstrates that overuse of antibiotics in animals can contribute to the emergence of antibiotic resistance. The volume of antibiotics used in animals is continuing to increase worldwide, driven by a growing demand for foods of animal origin, often produced through intensive animal husbandry."
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO said: "A lack of effective antibiotics is as serious a security threat as a sudden and deadly disease outbreak. Strong, sustained action across all sectors is vital if we are to turn back the tide of antimicrobial resistance and keep the world safe."
Responding to the announcement, BVA Senior Vice President Gudrun Ravetz said: "We welcome the WHO continuing to tackle this serious global health issue. Their guidelines echo the guidance BVA has long been issuing on the responsible use of antimicrobials.
"We agree that the prophylactic use of antimicrobials in healthy animals to prevent disease is never a substitute for good animal husbandry and management.
"Through cross-sector working, the UK is leading the way in significantly reducing antimicrobial usage, having already achieved the UK Government usage targets set for 2020.
"Critically Important Antimicrobials use is at a very low level in the UK, and, as recent Government data shows, is continuing to decrease. It is encouraging that WHO recognises that these vital medicines are sometimes needed, under veterinary judgment and prescription, as a last resort, to prevent the further spread of disease and to protect animal and human health."
The new guidelines can be downloaded here: http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia_guidelines/en/
Reference
The study, which examined cattle farmers’ and veterinary surgeons' opinions of pain-induced distress associated with disbudding, analgesia and attitudes and the use of non-steroidal anti-inflammatory drugs (NSAIDs), suggests that in particular, vets need to refine their understanding of farmers’ priorities, and how they guide clients on methods to improve calf welfare.
There have been a number of studies into the pain-induced distress resulting from the disbudding procedure. All methods of disbudding (apart from chemical cauterisation) in the UK require the use of a corneal nerve local anaesthetic blockade but there are currently no legislative requirements for the use of NSAIDs for disbudding – it is at the discretion of the farmer or veterinary surgeon carrying out the procedure. NSAIDs are routinely used in companion animals and equine practice, but less so in farm animals.
This new study, conducted by researchers at the Royal Veterinary College (RVC) in Hertfordshire and Aran Vet Clinic in Gwynedd, looked at the attitudes of farmers and vets on pain perception and pain management methods for disbudding. A total of 118 vets and 140 farmers contributed to the study. Of the respondents:
The study concluded that veterinary surgeons underestimate the influences of welfare and analgesic duration and effectiveness on farmers' decisions, and overrated cost impact. This perception could have a negative effect on veterinary recommendation.
The authors of the study therefore advise that steps should be taken to address the current inadequacies in the communications between vets and clients in conveying the practicalities and potential benefits of using NSAIDs.
Dr Troy Gibson, PhD, PGDipSci, BSc, Lecturer in Animal Welfare Science at the Royal Veterinary College said: "Despite the large amount of evidence of the benefits of NSAIDs for disbudding, it is disappointing that their use is still not widespread. This may partly be due to the only recent licencing of one NSAID for cattle. However, from our work it is clear that one of the key barriers to wider uptake is the breakdown in communication between veterinarians and their clients in conveying the cost, practicalities and potential benefits of NSAID use for disbudding. The wider use of NSAIDs in combination with local anaesthetics during disbudding would significantly improve calf welfare."
This only affects batch number C967336A, expires before 07/2020. Any other batches of Tylan 200 Injection are not affected and may continue to be distributed.
Elanco is contacting wholesale dealers and veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information regarding the recall, please contact Ms Victoria Haslingden 01256 779519 or email elanco_orders@lilly.com
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."
Norbrook Laboratories has announced the addition of new indications to its Loxicom (meloxicam) products, two regarding its use in cats, and the other in calves.
Loxicom 5mg/ml solution for injection for dogs and cats is now indicated for the management of post-operative pain in cats. An injection given around the time of surgery can be followed up with a course of Loxicom 0.5 mg/ml oral suspension for cats. Alternatively, for cats where no follow-up oral treatment is possible, for example with feral cats, a larger dose of the injectable formulation can be given at the time of surgery.
Norbrook's EU Veterinary Advisor, Rebekah Dudek MRCVS, said: "Norbrook is pleased to be able to now offer vets two on-licence choices in relation to how they want to use their 5mg/ml meloxicam injection in cats. This gives vets the flexibility they need to be able to deal effectively with the wide variety of cases they see every day."
Loxicom 20mg/ml solution for injection for cattle, pigs and horses has now been licenced for the relief of post-operative pain following dehorning in calves.
Norbrook says that the use of a non-steroidal antiinflammatory drug (NSAID) alongside local anaesthetic has clear benefits for animal welfare, and that use at this time is also shown to offer economic benefits to the farmer, with increased food-conversion efficiency compared to untreated calves1.
Rebekah said: "Dehorning in calves has long been known as a painful procedure, with a negative impact on feed intake in the post-operative period. With our latest licence, Loxicom 20mg/ml can now be used for relief of this potentially economically important post-operative pain in calves."
Containing ceftiofur (50mg/ml) and ketoprofen (150mg/ml), Curacef Duo is presented in a ready-to-use suspension for injection at a low volume dosage – 1 ml/50kg – which is identical to short-acting ceftiofur alone.
Virbac says that Curacef Duo’s combined action can help to minimise production losses in calves and offer a quick return to production for dairy cows affected by bacterial BRD. It can also improve welfare by targeting infection, inflammation and pain all at once, while its ease of use and simple dosing help to increase compliance. Curacef Duo offers a zero milk withdrawal period and an eight day withdrawal period in meat.
Brigitte Goasduf MRCVS, Large Animal Product Manager at Virbac, said: "In creating the first 'two-in-one' combination of two tried and trusted actives, the antibiotic ceftiofur and NSAID ketoprofen, we are offering practitioners an alternative to the treatment of bacterial BRD.
"We believe that the benefits Curacef Duo offers in terms of efficacy, ease of use and action on inflammation and pain, will be valued by both practitioners and farmers."
The British Veterinary Association and its specialist cattle division the British Cattle Veterinary Association have welcomed today's announcement by Defra that it is strongly minded to include a controlled cull of badgers as a key component of the bovine tuberculosis (TB) eradication plans for England.
The two associations have long supported the need to control TB in both cattle and wildlife, including the need for a targeted, humane cull of badgers in specific parts of the country.
Following a consultation exercise which closed in December 2010, Defra has today announced:
The BVA and BCVA jointly responded to Defra's 2010 consultation to say that the available science supported the case for a badger cull, alongside the need for stricter cattle control measures, in those areas where badgers are regarded as a significant contributor to the persistent presence of TB. The response also emphasised strongly that any cull of badgers had to be done in a humane and effective manner.
The BVA and BCVA say that today's announcement shows Defra has listened closely to their concerns. Through the consultation response the BVA and BCVA raised the issue of the efficacy of an industry-led cull using controlled shooting (as opposed to cage trapping and shooting) and stated firmly that any cull must be monitored for humaneness. Both of these issues have been considered in depth by Defra and appear to have been addressed in the plans.
The associations say they will be looking closely at the detail of the guidance issued today and will be responding to the consultation.
Harvey Locke, President of the BVA, said: "The BVA and BCVA have long argued for a targeted, humane badger cull to be used alongside stricter cattle controls. We believe that failure to tackle wildlife sources of TB infection has prolonged the presence and enhanced the spread of infection in all affected species populations.
"We recognise that this is a very emotive and difficult decision but we believe that the science supports this policy and we support Defra's commitment to tackling this devastating disease.
"We are particularly pleased that this announcement has not been delayed until after the summer recess, which demonstrates the seriousness of the need to tackle TB."
John Fishwick, President of BCVA, added: "We welcome today's announcement which indicates that a humane and carefully targeted cull of badgers can contribute to the control of this dreadful disease.
"We are particularly pleased that the veterinary profession's concerns that any cull must be humane and well monitored appear to have been listened to and we will now study the proposals in detail.
"An industry-led cull will be an enormous undertaking for everyone involved and it is vital that we get the detail right from the outset; for the sake of cattle, wildlife and industry."
Meanwhile, the RSPCA has expressed its devastation at the announcement.
According to the charity, new research has been published which shows that badger culling can more than double the risk of TB infecting cattle1. High-profile voices such as Sir David Attenborough and government adviser Lord John Krebs have also weighed in, saying a cull could "make the situation worse" and be "ineffective".
David Bowles, Director of Communications for the RSPCA, said: "Today is a black day for badgers - a day we have been dreading.
"At a time when the Welsh government has stepped back from a cull, the government in England is slowly shredding its own animal welfare credentials."
The RSPCA says it agrees that action is needed to combat bovine TB in cattle, but does not think action is synonymous with culling. The charity believes that vaccination of badgers, increased levels of testing, improved biosecurity and stricter controls on the movement of cattle are more effective ways of dealing with the problem in the long-term and eradicating bovine TB in cattle for good.
Colin Booty, senior scientist for the RSPCA, said: "The RSPCA is sympathetic to farmers struggling to cope with the effects of this crippling disease and thinks that the problem of bovine TB in cattle needs a sustainable and effective solution.
"But this is not such a solution. We believe that the government have taken the wrong fork in the road with this risky policy.
"This cull will contribute little or nothing to the long-term goal of eradicating TB nationally. Instead it will wipe out huge numbers of this much-loved species, including many animals which are healthy."
1 The New Medical Research Council study came from Imperial College London and were published in the Royal Society Journal Biology Letters. They were based on analysis of data from the 10-year Randomised Badger Culling Trial set up by the Department for Environment, Food and Rural Affairs (Defra) in 1998.
Ceva Animal Health has introduced Cevazuril, a toltrazuril-based oral solution for the control of diarrhoea in sucking pigs. Cevazuril is a one-dose treatment that comes in two pack sizes, both with dosing pumps, for convenient administration to large or small herds.
Ceva says newborn sucking piglets are especially sensitive to coccidiosis and infection may result in lost daily gain of almost 2kg in the first 28 days, due to diarrhoea. The control of coccidiosis using toltrazuril prevents damage to the intestinal mucosa caused by the developmental stages of Isospora suis, helping to preserve digestive function and maintain optimal growth rate.
Toltrazuril is absorbed very slowly in the intestine for longer-lasting action. It works on all intracellular developmental stages of coccidia and reduces oocyst production, even if administered after the appearance of the first oocysts in the faeces of the host.
According to the company, extensive trials showed that three day old piglets treated with toltazuril at 20mg/kg gained 801 grams at weaning and 1601 grams by the end of the post-weaning period compared to control pigs.
Cevazuril is available in a 250ml pack with a pump or a one litre pack with a multi-dose injector. It complements Ceva's swine portfolio which includes the antimicrobials Cevaxel, Coliscour, Florkem, Marbox, Spectam Scourhalt and Tiamvet.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at www.ceva.uk.com